logo
  

Nektar Collaborates With Merck KGaA, Pfizer To Evaluate NKTR-255 In Combination With Avelumab

Nektar Therapeutics (NKTR) has partnered with Merck KGaA and Pfizer Inc. to evaluate the combination of NKTR-255 with avelumab in urothelial carcinoma. Under the collaboration, Merck and Pfizer will include the combination of NKTR-255 plus avelumab in the new JAVELIN Bladder Medley study. Nektar will supply NKTR-255 for the trial.

NKTR-255 is wholly owned by Nektar. It is currently being evaluated in two separate clinical studies in both liquid and solid tumors.

Avelumab, which is marketed in the U.S. as BAVENCIO, is co-developed and co-commercialized by Merck KGaA and Pfizer Inc.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth... Caterpillar Inc. (CAT), a manufacturer of mining and construction equipment, reported Friday that fourth-quarter net income more than doubled to $2.12 billion or $3.91 per share from $780 million or $1.42 per share in the prior-year quarter. Excluding special items, adjusted net income for the quarter... United Airlines has opened its flight training school, United Aviate Academy, to bring out new pilots with a view to mainly empower women and people of color. The institute's first class of students is 80 percent women or people of color. This outpaces the airline's earlier goal to train about 5,000 new pilots at the school by 2030 with at least half being women or people of color.
RELATED NEWS
Follow RTT